Download PDF
Hamostaseologie 1992; 12(01): 001-006
DOI: 10.1055/s-0038-1660306
Übersichtsarbeit/Review Articles
Schattauer GmbH

Lipoproteine und Thrombozyten

E. Malle
1   Philipps-Universität, Zentrum Innere Medizin, Abteilung Endokrinologie und Stoffwechsel, Marburg/Lahn, Bundesrepublik Deutschland (Leiter: Prof. Dr. H. Kaffarnik)
,
G. M. Kostner
2   Karl-Franzens-Universität, Institut für Medizinische Biochemie, Graz, Österreich (Direktor: Prof. Dr. G. M. Kostner)
,
W. Sattler
3   Heart Research Institute, Dept. Medical Biochemistry, Sydney, Australien
› Author Affiliations
Further Information

Publication History

Publication Date:
26 June 2018 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Die Entstehung von Atherosklerose findet unter anderem ihren Ursprung in Läsionen des Endothels, die in Wechselwirkung mit aktivierten Thrombozyten, glatten Muskelzellen, Makrophagen, Wachstumsfaktoren, Lipoproteinen und Cholesterin zur Bildung atherosklerotischer Plaques führen können. Hohe Plasmakonzentrationen an Cholesterin, atherogenen Lipoproteinen, oxidativ modifizierten atherogenen Lipoproteinen sowie verminderte Plasmakonzentrationen an Antioxidanzien bedingen erhöhte Sensitivität und Reaktivität von Thrombozyten sowie gleichzeitig ein erhöhtes Risiko atherosklerotischer und kardiovaskulärer Veränderungen bei hyperlipämischen Patienten.

Schlüsselwörter

Thrombozytenaggregation - Lipoproteine - modifizierte Lipoproteine

Key words

Platelet aggregation - lipoproteins - modified lipoproteins
 

  • LITERATUR

  • 1 Abbate R, Modesti PA, Fortini A, Lombardi A, Matucci M, Gensini GF, Neri-Serneri GG, Fellin R, Valerio G, Crepaldi G. Decreased number of PGD2 binding sites on platelets from patients with type II a hyperlipoproteinemia. Atherosclerosis 1985; 54: 167-75.
    CrossrefPubMedGoogle Scholar
  • 2 Andrews HE, Aitken JW, Hassall DG, Skinner VO, Bruckdorfer KR. Intracellular mechanisms in the activation of human platelets by low-density lipoproteins. Biochem J 1987; 242: 559-64.
    CrossrefPubMedGoogle Scholar
  • 3 Ardlie NG, Selley ML, Simons LA. Platelet activation by oxidatively modified low density lipoproteins. Atherosclerosis 1989; 76: 117-24.
    CrossrefPubMedGoogle Scholar
  • 4 Aviram M, Brook JG, Lees AM, Lees RS. Low density lipoprotein binding to human platelets: role of charge and of specific amino acids. Biochem Biophys Res Commun 1981; 99: 308-18.
    CrossrefPubMedGoogle Scholar
  • 5 Aviram M, Brook JG. Characterization of the effect of plasma lipoproteins on platelet function in vitro. Haemostasis 1983; 13: 344-50.
    PubMedGoogle Scholar
  • 6 Aviram M, Brook JG. Plasma lipoprotein pattern and decreased platelet function in type V hyperlipoproteinemia. Isr J Med Sei 1985; 21: 898-904.
    PubMedGoogle Scholar
  • 7 Aviram M, Brook JG. Platelet activation by plasma lipoproteins. Progr Card Dis 1987; 30: 61-72.
    PubMedGoogle Scholar
  • 8 Aviram M, Deckelbaum RJ, Brook JG. Platelet function in a case with abetalipo-proteinemia. Atherosclerosis 1985; 57: 313-23.
    CrossrefPubMedGoogle Scholar
  • 9 Aviram M, Deckelbaum RJ. Intralipid infusion into humans reduced in vitro platelet aggregation and alters platelet lipid composition. Metabolism 1989; 38: 343-7.
    CrossrefPubMedGoogle Scholar
  • 10 Aviram M, Fuhrman B, Brook JG. Chylomicrons from patients with type V hyperlipoproteinemia inhibit platelet function. Atherosclerosis 1985; 56: 157-67.
    CrossrefPubMedGoogle Scholar
  • 11 Aviram M, Fuhrman B, Brook JG. Postprandial plasma lipoproteins in normal and hypertriglyceridaemic subjects and their in vitro effect on platelet activity: differences between saturated and polyunsaturated fats. Scand J Clin Lab Invest 1986; 46: 571-9.
    CrossrefPubMedGoogle Scholar
  • 12 Aviram M. Modified forms of low density lipoprotein affect platelet aggregation in vitro. Thromb Res 1989; 53: 561-7.
    CrossrefPubMedGoogle Scholar
  • 13 Baruch Y, Brook JG, Eidelman S, Aviram M. Increased concentration of high density lipoprotein in plasma and decreased Platelet aggregation in primary biliary cirrhosis. Atherosclerosis 1984; 53: 151-62.
    CrossrefPubMedGoogle Scholar
  • 14 Beitz J, Panse M, Förster W. Low density lipoproteins (LDL) from male volunteers stimulated the thromboxane formation by human platelets. Prostagland Leukot Med 1983; 10: 443-8.
    PubMedGoogle Scholar
  • 15 Brook JG, Marmur A, Berkovitch Y, Aviram M. Platelet adhesion in hyperlipidemic and hypertensive patients. Haemostasis 1985; 15: 371-6.
    PubMedGoogle Scholar
  • 16 Brox JH, Killie JE, Osterud B, Holme S, Nordoy A. Effects of cod liver oil on platelets and coagulation in familial hypercholesterolemia (type IIa). Acta Med Scand 1983; 213: 137-44.
    PubMedGoogle Scholar
  • 17 Bruckdorfer KR. The effect of plasma lipoproteins on platelet responsiveness and on platelet and vascular prostanoid synthesis. Prostagland Leukot Essent Fatty Acids 1989; 38: 247-54.
    CrossrefPubMedGoogle Scholar
  • 18 Carvalho ACA, Colman R, Lees RS. Platelet function in hyperlipoproteinemia. N Engl J Med 1974; 290: 434-8.
    CrossrefPubMedGoogle Scholar
  • 19 Catella F, Healy D, Lawson JA, Fitzgerald GA. 11-Dehydro thromboxane B2: A quantitative index of thromboxane A2 formation in the human circulation. Proc Natl Acad Sei 1986; 83: 5861-5.
    CrossrefPubMedGoogle Scholar
  • 20 Curtiss LK, Plow EF. Interaction of plasma lipoproteins with human platelets. Blood 1984; 64: 365-74.
    PubMedGoogle Scholar
  • 21 Davi G, Averna M, Novo S, Bargballo CM, Mogavero A, Notarbartolo A, Strano A. Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in hypercho-lesterolemic patients. Atherosclerosis 1989; 79: 79-83.
    CrossrefPubMedGoogle Scholar
  • 22 Desai K, Bruckdorfer R, Hutton RA, Owen JS. Binding of apo E-rich high density lipoprotein particles by saturable sites on human blood platelets inhibits agonist-induced platelet aggregation. J Lipid Res 1989; 30: 831-40.
    PubMedGoogle Scholar
  • 23 Di Minno G, Silver MJ, Cerbone AM, Raione A, Postiglione A, Mancini M. Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia. Arteriosclerosis 1986; 06: 203-11.
    CrossrefPubMedGoogle Scholar
  • 24 Ernst E. Plasma fibrinogen-an independent cardiovascular risk factor. J Int Med 1990; 227: 365-72.
    CrossrefPubMedGoogle Scholar
  • 25 Eynard AR, Tremoli E, Caruso D, Magni F, Sirtori CR, Galli G. Platelet formation of 12-hydroxyeicosatetraenoic acid and thromboxane B2 is increased in type IIA hyper-cholesterolemic subjects. Atherosclerosis 1986; 60: 61-6.
    CrossrefPubMedGoogle Scholar
  • 26 Farbiszewski R, Skrzydlewski ZI, Worowski K. The effect of lipoprotein fraction on adhesivness and aggregation of blood platelets. Thromb Diath Haemorrh 1969; 21: 88-92.
    PubMedGoogle Scholar
  • 27 Galle J, Mülsch A, Busse R, Bassenge E. Effect of native and oxidized low density lipoproteins on formation and inactivation of endothelium-derived relaxing factor. Arterioscleros Thromb 1991; 11: 198-203.
    PubMedGoogle Scholar
  • 28 Harker LA, Hazzard W. Platelet kinetic studies in patients with hyperlipoproteinemia: effects of clofibrate therapy. Circulation 1979; 60: 492-6.
    CrossrefPubMedGoogle Scholar
  • 29 Hassall DG, Desai K, Owen JS, Bruckdorfer KR. Detection of a protein in human platelet membranes which binds low-density lipoproteins. Platelets 1990; 01: 29-35.
    CrossrefPubMedGoogle Scholar
  • 30 Hassall DG, Owen JS, Bruckdorfer KR. The aggregation of isolated human platelets in the presence of lipoproteins and prostacyclin. Biochem J 1983; 216: 43-9.
    CrossrefPubMedGoogle Scholar
  • 31 Hayek T, Fuhrman B, Levy Y, Aviram M, Brook JG. Intralipid infusion in patients with familial hypercholesterolemia. Atherosclerosis 1990; 81: 61-9.
    CrossrefPubMedGoogle Scholar
  • 32 Higashihara M, Kinoshita M, Teramoto T, Kume S, Kurokawa K. The role of apo E in inhibitory effects of apo E-rich HDL on platelet function. FEBS Letters 1991; 282: 82-6.
    CrossrefPubMedGoogle Scholar
  • 33 Joist JH, Baker RK, Schonfeld G. Increased in vivo and in vitro platelet function in type II-and type IV-hyperlipoproteinemia. Thromb Res 1979; 15: 95-108.
    CrossrefPubMedGoogle Scholar
  • 34 Koller E, Koller F, Binder B. Purification and identification of the lipoprotein-binding proteins from human blood platelet membrane. J Biol Chem 1989; 264: 12412-8.
    PubMedGoogle Scholar
  • 35 Koller E, Koller F, Doleschal W. Specific binding sites on human platelets for plasma lipoproteim. Hoppe-Seyler’s Z Physiol Chem 1982; 363: 395-405.
    PubMedGoogle Scholar
  • 36 Koller E. Lipoprotein-binding proteins in the human platelet plasma membrane. FEBS Letters 1986; 200: 97-102.
    CrossrefPubMedGoogle Scholar
  • 37 Lavy A, Brook JG, Dankner G, Amotz AB, Aviram M. Enhanced in vitro oxidation of plasma lipoproteins derived from hypercho-lesterolemic patients. Metabolism 1991; 40: 794-9.
    CrossrefPubMedGoogle Scholar
  • 38 Malle E, Nimpf J, Leis HJ, Wurm H, Kostner GM. Postprandial hyperlipemia and platelet eicosanoid metabolism. Klin Wochenschr 1990; 68 (Suppl XXII) 315.
    PubMedGoogle Scholar
  • 39 Malle E, Sattler W, Prenner E, Leis HJ, Karàdi I, Knipping G, Romics L, Kostner GM. Platelet membrane fluidity in type IIA, type IIB and type IV hyperlipoproteinemia. Atherosclerosis 1991; 87: 159-67.
    CrossrefPubMedGoogle Scholar
  • 40 Molinas FC, Drucker E, Kordich L, Reynolds AM, Finkielman S. Platelet function and antithrombins in hyperlipoproteinemia type II a. Thromb Res 1981; 22: 427-35.
    CrossrefPubMedGoogle Scholar
  • 41 Mosconi C, Colli S, Tremoli E, Galli C. Phosphatidylinositol (PI) and Pi-associated arachidonate are elevated in platelet total membranes of type II a hypercholesterolemic subjects. Atherosclerosis 1988; 72: 129-34.
    CrossrefPubMedGoogle Scholar
  • 42 Nazih H, Devred D, Martin-Nizard F, Fruchart JC, Delbart C. Phosphatidylcholine breakdown in HDL3 stimulated platelets. Thromb Res 1990; 59: 913-20.
    CrossrefPubMedGoogle Scholar
  • 43 Nimpf J, Malle E, Leopold B, Wurm H, Kostner GM. Postprandial hyperlipidemia inhibits platelet aggregation without affecting prostanoid metabolism. Prostagland Leukot Essent Fatty Acids 1989; 37: 7-13.
    CrossrefPubMedGoogle Scholar
  • 44 Nimpf J, Malle E, Wurm H, Kostner GM. Is there any correlation between platelet activation and plasma lipoproteins?. Agents Actions 1987; 22: 366-8.
    CrossrefPubMedGoogle Scholar
  • 45 Nimpf J, Wurm H, Kostner GM, Kenner T. Platelet activation in normo-and hyperlipoproteinemias. Basic Res Cardiol 1986; 81: 437-53.
    CrossrefPubMedGoogle Scholar
  • 46 Nordoy A, Brox JH, Holme S, Killie JE, Lenner RA. Platelets and coagulation in patients with familial hypercholesterolemia (type IIa). Acta Med Scand 1983; 213: 129-35.
    PubMedGoogle Scholar
  • 47 Nordoy A, Lagarde M, Renaud S. Platelets during alimentary hyperlipaemia induced by cream and cod liver oil. Eur J Clin Invest 1984; 14: 339-45.
    CrossrefPubMedGoogle Scholar
  • 48 Owen JS, Hutton RA, Day RC, Bruckdorfer KR, McIntyre N. Platelet lipid composition and platelet aggregation in human liver disease. J Lipid Res 1981; 22: 423-30.
    PubMedGoogle Scholar
  • 49 Riess H, Merk W, Falkner C, Hiller E. Increased in vitro platelet aggregation in hypertriglyceridemias. Thromb Res 1986; 41: 281-9.
    CrossrefPubMedGoogle Scholar
  • 50 Schrör K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinemia and its modification by cholesterol-lowering drugs. Eicosanoids 1990; 03: 67-73.
    PubMedGoogle Scholar
  • 51 Shastri KM, Carvalho ACA, Lees RS. Platelet function and platelet lipid composition in the dyslipoproteinemias. J Lipid Res 1980; 21: 467-72.
    PubMedGoogle Scholar
  • 52 Shattil SJ, Bennett JS, Colman RW. Abnormalities of cholesterol-phospholipid composition in platelets and low-density lipoproteins in hyperbetalipoproteinemia. J Lab Clin Med 1977; 89: 341-53.
    PubMedGoogle Scholar
  • 53 Shmulewitz A, Brook JG, Aviram M. Native and modified low-density-lipoprotein interaction with human platelets in normal and homozygous familial-hypercholesterol-aemic subjects. Biochem J 1984; 224: 13-20.
    CrossrefPubMedGoogle Scholar
  • 54 Smith CCT, Wilson AP, Prichard BNC, Betteridge DJ. Platelet noradrenaline release in patients with familial hypercholesterolemia. Eur J Clin Invest 1989; 19: 246-50.
    CrossrefPubMedGoogle Scholar
  • 55 Smith II CM, Burris SM, Hunninghake DB, White JG. Altered platelet deformability in patients with type II a and type IV hyperlipoproteinemia. Am J Hematol 1988; 27: 247-52.
    CrossrefPubMedGoogle Scholar
  • 56 Steele M, Rainwater J. Effects of dietary and pharmacological alteration of serum lipids on platelet survival time. Circulation 1978; 58: 365-7.
    CrossrefPubMedGoogle Scholar
  • 57 Strano A, Davi G, Maderna M, Rini GB, Novo S, DiFede G, Mattina A, Natorbarto-lo A. Platelet sensitivity to prostacyclin and thromboxane production in hyperlipidemic Patients. Thromb Haemostas 1982; 48: 18-20.
    PubMedGoogle Scholar
  • 58 Strobl-Jäger E, Widhalm K, Sinzinger H. Influence of type II a, IIb and IV-hyperlipoproteinemia on platelet prostaglandin sensitivity, plasma thromboxane B2 and platelet half-life. Prostagland Leukot Med 1986; 25: 39-47.
    PubMedGoogle Scholar
  • 59 Stuart MJ, Gerrard JM, White JG. Effect of cholesterol on production of thromboxane B2 by platelets in vitro. N Engl J Med 1980; 302: 6-10.
    CrossrefPubMedGoogle Scholar
  • 60 Surya II, Mommersteeg M, Gorter M, Erkelens DW, Akkerman B. Abnormal platelet functions in a patient with abetalipopro-teinemia. Thromb Hemostas 1991; 65: 306-11.
    PubMedGoogle Scholar
  • 61 Tandon N, Harmon JT, Rodbard D, Jamieson GA. Thrombin receptors define responsiveness of cholesterol-modified platelets. J Biol Chem 1983; 258: 11840-5.
    PubMedGoogle Scholar
  • 62 Tremoli E, Maderna P, Colli S, Marazzoni G, Sirtori M, Sirtori CR. Increased platelet sensitivity and thromboxane B2 formation in type-II hyperlipoproteinaemic patients. Eur J Clin Invest 1984; 14: 329-33.
    CrossrefPubMedGoogle Scholar
  • 63 Tremoli E, Maderna P, Sirtori M, Sirtori CR. Platelet aggregation and malondialdehyde formation in type IIA hypercholeste-rolemic patients. Haemostasis 1979; 08: 47-53.
    PubMedGoogle Scholar
  • 64 Ylä-Herttulala S, Palinski W, Rosenfeld ME, Parthasarathy S, Carew TE, Butler S, Witzhum JL, Steinberg D. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 1989; 84: 1086-95.
    CrossrefPubMedGoogle Scholar
  • 65 Zahavi J, Betteridge JD, Jones NAG, Galton DJ, Kakkar VV. Enhanced in vivo platelet release reaction and malondial-dehyde formation on patients with hyperlipemia. Am J Med 1981; 70: 59-64.
    CrossrefPubMedGoogle Scholar
  • 66 Zucker ML, Bileyeu DS, Helmkamp GM, Harris WS, Dujovne CA. Effects of dietary fish oil on platelet function and plasma lipids in hyperlipoproteinemic and normal subjects. Atherosclerosis 1988; 73: 13-22.
    CrossrefPubMedGoogle Scholar
  • 67 Zucker ML, Trowbridge C, Krehbiel P, Jackson B, Chernoff SB, Dujovne CA. Platelet function in hypercholesterolemics before and after hypolipidemic drug therapy. Haemostasis 1986; 16: 57-64.
    PubMedGoogle Scholar